The NLMSF Board is pleased to announce the formation of a new Medical Advisory Committee for the NLMSF. We are honored that several of the finest researchers and clinicians in the field of sarcoma have agreed to serve on our Medical Advisory Committee. The Committee is presently composed of 16 members including its Chairman, NLMSF Board Member, LMS Survivor, Mitchell D. Achee, MD, a Diagnostic Radiologist Practicing in Denver, Colorado.
Dr. MITCHELL D. ACHEE, M.D.
Board Certified Diagnostic Radiologist, Denver, Colorado
University of Virginia School of Medicine Graduate M.D. (1977) Medical Internship and Residency in Diagnostic Radiology at Fitzsimons Army Medical Center, Aurora, ColoradoChair: Medical Advisory Committee, National Leiomyosarcoma Foundation
Dr. Achee, a Leiomyosarcoma survivor, diagnosed in 2011, has been in private practice for more than 25 years with Diversified Radiology of Colorado, P. C., a subspecialty radiology group of more than 60 radiologists in Denver, Colorado. Dr. Achee has served in both active duty and in the reserves in the Army. He served as Chief of the Diagnostic Branch, Dept. of Radiology at Fitzsimmons Army Medical Center. He was Chief of the Dept. of Radiology at the Franklin Clinic of the Colorado Permanente Medical Group, P. C. in Denver. He has held many leadership positions after his Army service: Chairman, Dept. of Radiology / Chairman, Credentials Committee at Centura Avista Hospital; President of the Medical Staff, Centura Avista Hospital; Chair, Dept. of Radiology at Exempla St. Joseph Hospital in Denver; Vice-President of operations and Hospital Affairs for Diversified Radiology of Colorado (encompassing 12 hospitals, 50 radiologists); Medical Advisory Committee for United Healthcare of Colorado; Denver Medical Society Board of Directors member.Currently, Dr. Achee is a member of the Connective Tissue Oncology Society (CTOS). He has focused on sarcoma patient support, advocacy, and education, as well as sarcoma research. He, along with his wife, established a patient support and education website (www.lmslifeline.com) as well as assisted in establishing the Rocky Mountain LMS Support Network for LMS patients throughout Colorado. Dr. Achee is a Sarcoma Alliance Board member.
Laurence H Baker DO
Professor Michigan Medicine – Sarcoma
University of Michigan Comprehensive Cancer Center Specialties:
Osteopathic Board of Oncology, Internal Medicine 51 years in practice
Area of Practice:
Survivorship for patients with soft tissue and bone sarcomas, collaborative clinical trials. The visionary for initiating the Sarcoma Alliance Through Research Collaboration (SARC) for the
advancement of sarcoma research and recognition of new researchers interested in sarcoma research.
Division of Surgical Oncology
Winship Cancer Institute
Emory University Hospital Midtown
Dr. Cardona is a board-certified surgeon and surgical oncologist who specializes in the management of complex gastrointestinal malignancies (such as stomach, pancreas, and liver cancers) and is an expert in the treatment of sarcomas.
Dr. Cardona is a leader and active member of both the Gastrointestinal Oncology and Sarcoma Workgroups at Emory University Hospital Midtown and collaborates with medical and radiation oncologists, gastroenterologists, and interventional radiologists to develop an individualized, multidisciplinary treatment plan for each patient.
Dr. Sant P Chawla
Assistant Professor of Medicine Harvard Medical School
Dana Farber/Harvard Cancer Center
Massachusetts General Hospital
Director of Sarcoma Clinical Research
Clinical Director of Sarcoma Oncology
Edwin Choy, MD, PhD, is an esteemed clinical oncologist in the MGH Center for Sarcoma and Connective Tissue Oncology. As the Director of Sarcoma Research at the Division of Hematology Oncology at MGH, he specializes in the medical management of patients with sarcomas and maintains an active research focus that encompasses diverse areas of sarcoma therapy, ranging from use of nanotechnology and translational research aimed at developing new molecular therapies for treating sarcomas to preclinical studies using cell lines and animal models to better understand biochemical predictors of sarcoma therapy.
His training includes molecular biophysics and biochemistry with post-doctoral in internal medicine, hematology/oncology and a program in Medical Genetics through the Broad Institute of Harvard and Massachusetts Institute of Technology.
Dr. Choy serves as an advisor on several Scientific Advisory Boards including Liddy Shriver, Amgen, Pfizer, and Bayer. He was the Clinical Trial Project Leader for NCIs Specialized Program of Research Excellence (SPORE) in collaboration with the Sarcoma Alliance and Medical Co-Chair for Clinical Trial ARST 1321.
Rashmi Chugh, M.D. (Medical Oncologist)
Clinical Assistant Professor of Internal Medicine—Hematology/Oncology
University of Michigan Health System
Washington University School of Medicine in St. Louis
CERTIFICATIONS & LICENSURE
MI State Medical License 2001 – 2017
American Board of Internal Medicine-Internal Medicine, 2001
American Board of Internal Medicine-Medical Oncology, 2006
Dr. Rashmi Chugh is a well-respected medical oncologist in Ann Arbor, Michigan, and is affiliated with multiple hospitals in the area, including University of Michigan Hospitals and Health Centers and Veterans Affairs Ann Arbor Healthcare System. She received her medical degree from Washington University School of Medicine in St. Louis and her residency at the University of Michigan in Internal Medicine in 2002. Her fellowship followed in Hematology/Medical Oncology, University of Michigan Health System, 2005, and she has been in practice for 17 years.
Dr. Chugh was recognized for her research on CMS Meaningful Use Stage 1 Certification, EpicCare Ambulatory EMR, Epic Systems Corporation in 2012 and CMS Meaningful Use Stage 1 Certification, EpicCare Ambulatory EMR, Epic Systems Corporation in 2013.
She is one of 31 doctors at University of Michigan Hospitals and Health Centers and one of 30 at Veterans Affairs Ann Arbor Healthcare System who specializes in Medical Oncology. She conducts clinical trials of investigational agents or novel combinations in sarcoma patients.
Treatment of molecularly-selected bone and soft tissue sarcomas with CDK4 inhibitors to synchronize and sensitize tumor cells to chemotherapy.
Integrating ex vivo functional drug sensitivity and next generation sequencing of metastatic osteosarcoma to predict effective targeted drug combinations.
Identifying, characterizing and targeting kinase alterations in sarcomas.
Mihaela Druta, MD
Harvard Medical Pathology – Dana FarberBrighan & Women’s Cancer Center
DF/HCC PROGRAM AFFILIATION
Associate Professor of Medicine, Harvard Medical School
Erlinda Maria Gordon, M.D.
Dr. Gordon is an experienced Pediatric Hematologist-Oncologist, cancer drug developer, biopharmaceutical founder and executive with a proven track record in translational biomedical research, patient care and cancer drug development.
Dr. Kenneth Gundle
Dr. Kenneth Gundle is an orthopedic surgeon in Portland, Oregon and is affiliated with OHSU Hospital. He received his medical degree from Harvard Medical School and has been in practice for 6-10 years. He is one of 19 doctors at OHSU Hospital who specialize in Orthopedic Surgery.
Subspecialties: General Orthopedic Surgery, Musculoskeletal Oncology/Cancer
Dr. Kenneth Robert Gundle is trained in the preservation, investigation and restoration of the form and function of the extremities, spine and associated structures by medical, surgical and physical means including the patients with musculoskeletal problems which include congenital deformities, trauma, infections, tumors, metabolic disturbances of the musculoskeletal system, deformities, injuries and degenerative diseases of the spine, hands, feet, knee, hip, shoulder and elbow in children and adults. Patients with primary and secondary muscular problems and the effects of central or peripheral nervous system lesions of the musculoskeletal system are also concerned.
Professor and Vice Chair for Basic & Translational Research, Department of Radiation Oncology
Professor, Department of Pharmacology & Cancer Biology
Kirsch Lab- Duke University Medical Center, Duke Cancer Institute
My clinical interests are the multi-modality care of patients with bone and soft tissue sarcomas and developing new sarcoma therapies. My laboratory interests include utilizing mouse models of cancer to study cancer and radiation biology in order to develop new cancer therapies in the pre-clinical setting.
Associate Professor, Dept. of Pathology, Division of Pathology/Lab Medicine, Director, Dept. of Pathology, University of Texas MD Anderson Cancer Center University of Texas, MD Anderson Cancer Center, Houston, Texas Selective (soft Tissue) Pathology Fellowship Training Program, Houston, Texas University of Texas, Southwestern Medical Center Graduate (MD/PhD program, 2000)
Clinical Residency, Anatomic Pathology, Brigham and Women’s Hospital, Boston, MA University of Texas Southwestern Medical Center, Dallas, TX, Medical Scientist Training Program (2002)
University of Texas Southwestern Graduate School of Biomedical Science, Dallas, Texas (2002)
Dr. Lazar is a distinguished medical pathologist with considerable background and training in the area of soft tissue sarcoma. He has had an administrative appointment as Director, Dept. of Pathology at M.D. Anderson with selective Soft Tissue Pathology Fellowship training, as well as a Faculty member at M. D. Anderson’s Sarcoma Research Center. Postgraduate training has been extensive, with a Clinical Fellowship, Soft Tissue Pathology at Brigham and Women’s Hospital, Boston, MA from 2002-2003. He has also been a committee member, American Joint Cancer Committee Soft Tissue Sarcoma (AJCC), 6th/7th Edition Task Force from 2007 to the present. Dr. Lazar has been a committee member of the Cancer Committee, Sarcoma Section, College of American Pathologists (CAP, since 2007. He is also a member of the Sarcoma Multidisciplinary Clinical Center, Steering Committee since 2006, and is on the Teaching Faculty, Baylor Molecular Genetics, Baylor College of Medicine as of 2009.
Dr. Lazar was invited as a consultant to the First International Conference on Sarcoma Pathology, Miami, Florida, sponsored by the Office of Rare Diseases, NCI/NIH. Dr. Lazar was a panelist by invitation-only to the roundtable event for approximately 50 international thought leaders to establish priorities for basis and translational research in 2009.
Dr. Robert Maki, MD
New Hyde Park, New York
Dr. Maki is an internationally -renowned sarcoma cancer physician and researcher, serving as the Director of Experimental Therapeutics of the Don Monti Division of Medical Oncology and Hematology at North Shore University Hospital and Long Island Jewish Medical Center, and Director of the Center for New Cancer Therapies at Northwell health Cancer Institute.
National Cancer Institute-designated Cancer Center at CSHL. He has extensive expertise and experience in the development of novel therapies for the treatment of soft tissue and bone sarcomas. he oversees the expansion of the basic and translational sarcoma cancer research program in collaboration with CSHL. He will be pursuing bench -to-bedside research and clinical trials to improve the outcome of patients with aggressive cancer using promising new agents. He has dedicated his life to finding a cure for sarcoma.
Dr. Sujana Movva
Menatology/Oncology specialist/researcher Fox Chase Cancer Center – Philadelphia
Dr. Sujana Movva is a medical oncologist in Philadelphia, Pennsylvania and is affiliated with Fox Chase Cancer Center-American Oncologic Hospital. She received her medical degree from University of Western Ontario and has been in practice between 11-20 years. She is one of 38 doctors at Fox Chase Cancer Center-American Oncologic Hospital who specialize in Medical Oncology.
Dr. Scott H. Okuno, M.D.
Mayo Clinic, Rochester, MN
- Medical officer, Sarcoma Alliance for Research Through Collaboration (SARC), 2011-present
- Founding and active member, Midwest Sarcoma Trials Partnership, 2011-present
- Active member, Sarcoma Working Group, Radiation Therapy Oncology Group, 2010-present
- Assistant Professor, University of Washington School of Medicine
- Assistant Member, Fred Hutchinson Cancer Research Center
Dr. RAPHAEL POLLOCK, M.D. / Ph.D., F>A>C>S
Director of the Division of Surgical Oncology at the Arthur G. Hospital, Ohio State University Comprehensive Cancer Center, Columbus, OhioPreviously Head of the Division of Surgery at the University of Texas, M.D. Anderson Cancer Center, Houston, with a 31-year affiliation with M.D. Anderson St. Louis University School of Medicine GraduateSurgical residencies at Rush-Presbyterian, St. Luke’s Medical Center, and University of Chicago Hospital
Dr. Pollock is world renowned and respected as a gifted cancer surgeon, researcher, and passionate educator of physicians in training. Dr. Pollock is principal investigator of an $11.5 million National Cancer Institute (NCI) grant to support collaborative sarcoma (Programs of Research Excellence SPORE grant), awarded to the Sarcoma Alliance for Research for Collaboration (SARC). His expertise and international reputation as an experienced surgical leader, as well as a distinguished academician and researcher, allow for the continued pairing of innovative surgical solutions with discoveries in the burgeoning field of cancer genomics. The James Hospital is ranked by U. S. News and World Report as a “top of the top cancer hospitals in the nation,” and highly rated and funded by the NCI, with designation as one of only 41 National Cancer Institute-designated cancer centers to conduct both phase I and phase II clinical trials.
Dr. Pollock will also be a professor and the Director of the Division of Surgical at the Ohio State University Wexner Medical Center College of the Medicine’s department of surgery. As an international researcher and academician, Dr. Pollock’s focus is research and development of therapeutics for tumor suppression in soft tissue sarcomas, with a multidisciplinary/multiple level treatment approaches.
Dr. Richard Riedel, MD, Medical Oncologist
Duke Cancer Center, Durham, NC
Associate Professor of Medicine / Research: novel therapies of soft tissue and bone sarcomas
I am a medical oncologist who focuses on bone and soft tissue cancers called sarcomas. I love spending time with my patients. They often have a sense of awareness about their condition that’s truly unique and rewarding. I partner with each patient so they know the full set of options available for treatment and can make an informed decision about the approach that is best for them. I’ve wanted to pursue medicine for as long as I can remember. I find cancer fascinating because of its ability to evade the immune system. The body fails to recognize cancer as being foreign. When I am not at work, I love spending time with my family and enjoy long distance running.
Dr. Arun Singh Medical oncologist
Santa Monica, California UCLA Medical Center and UCLA Medical Center Santa Monica.
Dr. Arun Singh, assistant professor and Co-Director of the Medical Oncology Sarcoma Program, reviews the diagnosis, treatment and follow-up care of patients diagnosed with sarcomas – a spectrum of rare diseases. He discusses the importance of the multidisciplinary approach in caring for patients with these malignancies. He presents the evolving biologic understanding of sarcomas and how these new insights are leading to the development of the next generation of therapies for these patients. Additionally, Dr. Singh is the assistant professor in the Department of Medicine, Division of Hematology/Oncology at the David Geffen School of Medicine UCLA. Dr. Singh is a Hematologist and Medical Oncologist whose practice focuses on the treatment of bone and soft tissue sarcomas. Dr. Singh’s research focus is on developing novel therapies for patients with sarcomas. In the preclinical setting, he works on elucidating the mechanisms contributing to the promotion of growth in cancer cells and optimizing the use of targeted therapy in specific sarcoma subtypes. The insights gained from these efforts are then translated into the clinic in the form of new drugs in early stage Phase I and II clinical trials for sarcomas where there is an unmet clinical need.
As a hematologist/oncologist in Texas, Dr. Somaiah is capable of diagnosing and treating patients with blood-related disorders, malignancies, or cancers. Dr. Somaiah may treat a range of conditions ranging from the common to the very rare and complex. As a result, Dr. Somaiah may provide care as part of a multidisciplinary team, working in conjunction with other specialists to ensure the highest possible standard of care.
Scott Michael Schuetze MD, PhD
Area of Practice:
I’m a faculty member in the Hematology/Oncology Division of the Department of Internal Medicine. My clinical focus is caring for patients with sarcomas (cancers of connective tissue). I’m also leading clinical research designed to identify better tolerated and more effective treatments for sarcoma. Right now we’re working on Phase II trials (focused on the safety and activity of new treatments) and Phase III trials (focused on comparing small-group results to current treatment standards).
Brian Van Tine, MD, PhD
Department of Pathology
Stanford University Medical Center